Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
Novartis | April 06, 2017
Novartis announced today that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing conditions including regulatory approvals. The financial and other terms of this transaction are not disclosed.